Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Regeneron Pharmaceuticals    REGN

REGENERON PHARMACEUTICALS (REGN)
My previous session
Most popular
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
12/10/2018 12/11/2018 12/12/2018 12/13/2018 12/14/2018 Date
377.59(c) 375.72(c) 377.96(c) 378.51(c) 381.17(c) Last
876 066 814 742 601 238 478 928 727 245 Volume
+1.28% -0.50% +0.60% +0.15% +0.70% Change
More quotes
Financials (USD)
Sales 2018 6 495 M
EBIT 2018 2 773 M
Net income 2018 1 992 M
Finance 2018 3 750 M
Yield 2018 -
Sales 2019 7 160 M
EBIT 2019 2 984 M
Net income 2019 2 263 M
Finance 2019 5 991 M
Yield 2019 -
P/E ratio 2018 20,14
P/E ratio 2019 19,69
EV / Sales2018 5,66x
EV / Sales2019 4,82x
Capitalization 40 527 M
More Financials
Company
Regeneron Pharmaceuticals specializes in research, development, producing, and selling drugs used in treating ophthalmologic and inflammatory diseases and cancers. Sales break down by activity as follows: - sales of products (63.3%); - supply of collaborative services (30.9%): working with... 
More about the company
Surperformance© ratings of Regeneron Pharmaceuticals
Trading Rating : Investor Rating :
More Ratings
Latest news on REGENERON PHARMACEUTICALS
12/04REGENERON PHARMACEUTICALS : reports positive data from Phase I REGN1979 trial
AQ
12/03REGENERON PHARMACEUTICALS : Presents positive data at ash for regn1979 cd20xcd3 ..
AQ
11/29MANAGEMENT TRACKS : PolarityTE and Foamix hire first chief commercial officers
AQ
11/26Fauci details goals of new Ebola trial
AQ
11/20REGENERON PHARMACEUTICALS : Announces Upcoming Investor Conference Presentation
PR
11/13ZIOPHARM ONCOLOGY : Announces Immuno-oncology Clinical Supply Agreement with Reg..
AQ
11/12Ziopharm in Supply Agreement with Regeneron to Study Glioblastoma Treatment
DJ
11/11SANOFI : ODYSSEY OUTCOMES investigators highlight at AHA that Praluent® (alirocu..
AQ
11/07REGENERON PHARMACEUTICALS : FDA Grants Priority Review for Dupixent (dupilumab) ..
AQ
11/06Regeneron, Sanofi Get FDA Priority Review for Dupixent in Adolescents
DJ
More news
Analyst Recommendations on REGENERON PHARMACEUTICALS
More recommendations
Sector news : Bio Therapeutic Drugs
12/14FDA Approves Herceptin Biosimilar Herzuma
DJ
12/13Lilly, Incyte Get FDA Fast-Track Designation for Baricitinib in Systemic Lupu..
DJ
12/10Almost half of S&P 500 stocks in a bear market
RE
12/10ROCHE : Gilead Sciences snares Roche veteran O'Day as CEO
RE
12/10LONZA : to Establish Biomanufacturing Base in China
DJ
More sector news : Bio Therapeutic Drugs
Chart REGENERON PHARMACEUTICALS
Duration : Period :
Regeneron Pharmaceuticals Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends REGENERON PHARMACEUTICALS
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 429 $
Spread / Average Target 12%
EPS Revisions
Managers
NameTitle
Leonard S. Schleifer Co-President, Chief Executive Officer & Director
George Damis Yancopoulos Co-President, Director & Chief Scientific Officer
P. Roy Vagelos Chairman
Robert E. Landry Chief Financial Officer & Senior VP-Finance
Michael S. Brown Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
REGENERON PHARMACEUTICALS1.39%40 527
GILEAD SCIENCES-8.47%84 823
VERTEX PHARMACEUTICALS15.72%43 460
GENMAB3.84%9 952
SAREPTA THERAPEUTICS INC114.81%7 987
NEUROCRINE BIOSCIENCES, INC.-8.06%6 469